Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 241 to 251 of 251 entries
Sorted by: Best Match Show Resources per page
The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei.

The American journal of surgical pathology

Hissong E, Yantiss RK.
PMID: 33417324
Am J Surg Pathol. 2022 Jan 01;46(1):e27-e42. doi: 10.1097/PAS.0000000000001662.

Appendiceal mucinous neoplasms show a range of morphologic features and biological risk. At one end of the spectrum, high-grade adenocarcinomas are cytologically malignant with infiltrative invasion, lymph node metastases, and behavior similar to that of extra-appendiceal mucinous adenocarcinomas. At...

Cite
Hissong E, Yantiss RK. The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. Am J Surg Pathol. 2022;46(1):e27-e42doi: 10.1097/PAS.0000000000001662.
Hissong, E., & Yantiss, R. K. (2022). The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. The American journal of surgical pathology, 46(1), e27-e42. https://doi.org/10.1097/PAS.0000000000001662
Hissong, Erika, and Yantiss, Rhonda K. "The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei." The American journal of surgical pathology vol. 46,1 (2022): e27-e42. doi: https://doi.org/10.1097/PAS.0000000000001662
Hissong E, Yantiss RK. The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. Am J Surg Pathol. 2022 Jan 01;46(1):e27-e42. doi: 10.1097/PAS.0000000000001662. PMID: 33417324.
Copy Download .nbib Format: NLM
Evaluation of peripherin in biofluids of patients with motor neuron diseases.

Annals of clinical and translational neurology

Sabbatini D, Raggi F, Ruggero S, Seguso M, Mandrioli J, Cagnin A, Briani C, Toffanin E, Gizzi M, Fortuna A, Bello L, Pegoraro E, Musso G, Sorarù G.
PMID: 34264016
Ann Clin Transl Neurol. 2021 Aug;8(8):1750-1754. doi: 10.1002/acn3.51419. Epub 2021 Jul 15.

Peripherin (PRPH), a type III intermediate filament, assembles with neurofilaments in neurons of the peripheral nervous system, including lower motor neurons (LMN). To evaluate the role of PRPH in LMN degeneration, we assessed PRPH and neurofilament light chain (NfL)...

Cite
Sabbatini D, Raggi F, Ruggero S, et al. Evaluation of peripherin in biofluids of patients with motor neuron diseases. Ann Clin Transl Neurol. 2021;8(8):1750-1754doi: 10.1002/acn3.51419.
Sabbatini, D., Raggi, F., Ruggero, S., Seguso, M., Mandrioli, J., Cagnin, A., Briani, C., Toffanin, E., Gizzi, M., Fortuna, A., Bello, L., Pegoraro, E., Musso, G., & Sorarù, G. (2021). Evaluation of peripherin in biofluids of patients with motor neuron diseases. Annals of clinical and translational neurology, 8(8), 1750-1754. https://doi.org/10.1002/acn3.51419
Sabbatini, Daniele, et al. "Evaluation of peripherin in biofluids of patients with motor neuron diseases." Annals of clinical and translational neurology vol. 8,8 (2021): 1750-1754. doi: https://doi.org/10.1002/acn3.51419
Sabbatini D, Raggi F, Ruggero S, Seguso M, Mandrioli J, Cagnin A, Briani C, Toffanin E, Gizzi M, Fortuna A, Bello L, Pegoraro E, Musso G, Sorarù G. Evaluation of peripherin in biofluids of patients with motor neuron diseases. Ann Clin Transl Neurol. 2021 Aug;8(8):1750-1754. doi: 10.1002/acn3.51419. Epub 2021 Jul 15. PMID: 34264016; PMCID: PMC8351396.
Copy Download .nbib Format: NLM
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia.

HemaSphere

Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, Campeggio M, De Novi LA, Soscia R, Oggioni C, Mussolin L, Biondi A, Guarini A, Valsecchi MG, Conter V, Biffi A, Basso G, Foà R, Cazzaniga G.
PMID: 33655199
Hemasphere. 2021 Feb 24;5(3):e543. doi: 10.1097/HS9.0000000000000543. eCollection 2021 Mar.

Minimal residual disease (MRD) is the most powerful prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Real-time quantitative polymerase chain reaction (RQ-PCR) represents the gold standard for molecular MRD assessment and risk-based stratification of front-line treatment. In the protocols...

Cite
Della Starza I, Nunes V, Lovisa F, et al. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. Hemasphere. 2021;5(3):e543doi: 10.1097/HS9.0000000000000543.
Della Starza, I., Nunes, V., Lovisa, F., Silvestri, D., Cavalli, M., Garofalo, A., Campeggio, M., De Novi, L. A., Soscia, R., Oggioni, C., Mussolin, L., Biondi, A., Guarini, A., Valsecchi, M. G., Conter, V., Biffi, A., Basso, G., Foà, R., & Cazzaniga, G. (2021). Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. HemaSphere, 5(3), e543. https://doi.org/10.1097/HS9.0000000000000543
Della Starza, Irene, et al. "Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia." HemaSphere vol. 5,3 (2021): e543. doi: https://doi.org/10.1097/HS9.0000000000000543
Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, Campeggio M, De Novi LA, Soscia R, Oggioni C, Mussolin L, Biondi A, Guarini A, Valsecchi MG, Conter V, Biffi A, Basso G, Foà R, Cazzaniga G. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. Hemasphere. 2021 Feb 24;5(3):e543. doi: 10.1097/HS9.0000000000000543. eCollection 2021 Mar. PMID: 33655199; PMCID: PMC7909459.
Copy Download .nbib Format: NLM
High rates of early remission pattern in adult-onset compared with earlier-onset idiopathic generalized epilepsy: A long-term follow-up study.

Seizure

Cerulli Irelli E, Orlando B, Salamone EM, Fisco G, Barone FA, Morano A, Fanella M, Fattouch J, Manfredi M, Giallonardo AT, Di Bonaventura C.
PMID: 34864252
Seizure. 2021 Nov 26;94:52-56. doi: 10.1016/j.seizure.2021.11.019. Epub 2021 Nov 26.

OBJECTIVE: To investigate electroclinical characteristics and prognostic patterns of adult-onset vs. younger-onset idiopathic generalized epilepsy (IGE) patients during long-term follow-up.METHODS: In this single-center retrospective cohort comparative study, adult-onset IGE was defined as onset after 20 years of age. Patients...

Cite
Cerulli Irelli E, Orlando B, Salamone EM, et al. High rates of early remission pattern in adult-onset compared with earlier-onset idiopathic generalized epilepsy: A long-term follow-up study. Seizure. 2021;94:52-56doi: 10.1016/j.seizure.2021.11.019.
Cerulli Irelli, E., Orlando, B., Salamone, E. M., Fisco, G., Barone, F. A., Morano, A., Fanella, M., Fattouch, J., Manfredi, M., Giallonardo, A. T., & Di Bonaventura, C. (2021). High rates of early remission pattern in adult-onset compared with earlier-onset idiopathic generalized epilepsy: A long-term follow-up study. Seizure, 9452-56. https://doi.org/10.1016/j.seizure.2021.11.019
Cerulli Irelli, Emanuele, et al. "High rates of early remission pattern in adult-onset compared with earlier-onset idiopathic generalized epilepsy: A long-term follow-up study." Seizure vol. 94 (2021): 52-56. doi: https://doi.org/10.1016/j.seizure.2021.11.019
Cerulli Irelli E, Orlando B, Salamone EM, Fisco G, Barone FA, Morano A, Fanella M, Fattouch J, Manfredi M, Giallonardo AT, Di Bonaventura C. High rates of early remission pattern in adult-onset compared with earlier-onset idiopathic generalized epilepsy: A long-term follow-up study. Seizure. 2021 Nov 26;94:52-56. doi: 10.1016/j.seizure.2021.11.019. Epub 2021 Nov 26. PMID: 34864252.
Copy Download .nbib Format: NLM
Hyperglycemia-induced Immune System Disorders in Diabetes Mellitus and the Concept of Hyperglycemic Memory of Innate Immune Cells: A perspective.

Endocrine, metabolic & immune disorders drug targets

Lisco G, Giagulli VA, De Pergola G, Guastamacchia E, Jirillo E, Triggiani V.
PMID: 34561995
Endocr Metab Immune Disord Drug Targets. 2021 Sep 24; doi: 10.2174/1871530321666210924124336. Epub 2021 Sep 24.

No abstract available.

Cite
Lisco G, Giagulli VA, De Pergola G, et al. Hyperglycemia-induced Immune System Disorders in Diabetes Mellitus and the Concept of Hyperglycemic Memory of Innate Immune Cells: A perspective. Endocr Metab Immune Disord Drug Targets. 2021;doi: 10.2174/1871530321666210924124336.
Lisco, G., Giagulli, V. A., De Pergola, G., Guastamacchia, E., Jirillo, E., & Triggiani, V. (2021). Hyperglycemia-induced Immune System Disorders in Diabetes Mellitus and the Concept of Hyperglycemic Memory of Innate Immune Cells: A perspective. Endocrine, metabolic & immune disorders drug targets, . https://doi.org/10.2174/1871530321666210924124336
Lisco, Giuseppe, et al. "Hyperglycemia-induced Immune System Disorders in Diabetes Mellitus and the Concept of Hyperglycemic Memory of Innate Immune Cells: A perspective." Endocrine, metabolic & immune disorders drug targets vol. (2021). doi: https://doi.org/10.2174/1871530321666210924124336
Lisco G, Giagulli VA, De Pergola G, Guastamacchia E, Jirillo E, Triggiani V. Hyperglycemia-induced Immune System Disorders in Diabetes Mellitus and the Concept of Hyperglycemic Memory of Innate Immune Cells: A perspective. Endocr Metab Immune Disord Drug Targets. 2021 Sep 24; doi: 10.2174/1871530321666210924124336. Epub 2021 Sep 24. PMID: 34561995.
Copy Download .nbib Format: NLM
Covid-19 in Man: A Very Dangerous Affair.

Endocrine, metabolic & immune disorders drug targets

Lisco G, Giagulli VA, De Pergola G, De Tullio A, Guastamacchia E, Triggiani V.
PMID: 33388025
Endocr Metab Immune Disord Drug Targets. 2021;21(9):1544-1554. doi: 10.2174/1871530321666210101123801.

The novel pandemic of Coronavirus disease 2019 (COVID-19) has become a public health issue since March 2020, with more than 30 million people found to be infected worldwide. Men may be considered to be at a higher risk of...

Cite
Lisco G, Giagulli VA, De Pergola G, et al. Covid-19 in Man: A Very Dangerous Affair. Endocr Metab Immune Disord Drug Targets. 2021;21(9):1544-1554doi: 10.2174/1871530321666210101123801.
Lisco, G., Giagulli, V. A., De Pergola, G., De Tullio, A., Guastamacchia, E., & Triggiani, V. (2021). Covid-19 in Man: A Very Dangerous Affair. Endocrine, metabolic & immune disorders drug targets, 21(9), 1544-1554. https://doi.org/10.2174/1871530321666210101123801
Lisco, Giuseppe, et al. "Covid-19 in Man: A Very Dangerous Affair." Endocrine, metabolic & immune disorders drug targets vol. 21,9 (2021): 1544-1554. doi: https://doi.org/10.2174/1871530321666210101123801
Lisco G, Giagulli VA, De Pergola G, De Tullio A, Guastamacchia E, Triggiani V. Covid-19 in Man: A Very Dangerous Affair. Endocr Metab Immune Disord Drug Targets. 2021;21(9):1544-1554. doi: 10.2174/1871530321666210101123801. PMID: 33388025.
Copy Download .nbib Format: NLM
Eating Disorders and Type 1 Diabetes: a perspective.

Endocrine, metabolic & immune disorders drug targets

Marucci S, De Iaco G, Lisco G, Mariano F, Giagulli VA, Guastamacchia E, De Pergola G, Triggiani V.
PMID: 34751127
Endocr Metab Immune Disord Drug Targets. 2021 Nov 09; doi: 10.2174/1871530321666211109152353. Epub 2021 Nov 09.

Patients with type 1 diabetes (T1D) are at risk of clinical eating disorders (EDs) and disordered eating behaviors (DEBs) than the general population. This burden is related mainly to diabetes-related physical and psychosocial issues especially beginning during childhood. DEBs...

Cite
Marucci S, De Iaco G, Lisco G, et al. Eating Disorders and Type 1 Diabetes: a perspective. Endocr Metab Immune Disord Drug Targets. 2021;doi: 10.2174/1871530321666211109152353.
Marucci, S., De Iaco, G., Lisco, G., Mariano, F., Giagulli, V. A., Guastamacchia, E., De Pergola, G., & Triggiani, V. (2021). Eating Disorders and Type 1 Diabetes: a perspective. Endocrine, metabolic & immune disorders drug targets, . https://doi.org/10.2174/1871530321666211109152353
Marucci, Simonetta, et al. "Eating Disorders and Type 1 Diabetes: a perspective." Endocrine, metabolic & immune disorders drug targets vol. (2021). doi: https://doi.org/10.2174/1871530321666211109152353
Marucci S, De Iaco G, Lisco G, Mariano F, Giagulli VA, Guastamacchia E, De Pergola G, Triggiani V. Eating Disorders and Type 1 Diabetes: a perspective. Endocr Metab Immune Disord Drug Targets. 2021 Nov 09; doi: 10.2174/1871530321666211109152353. Epub 2021 Nov 09. PMID: 34751127.
Copy Download .nbib Format: NLM
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.

JAMA internal medicine

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE.
PMID: 34901997
JAMA Intern Med. 2021 Dec 13; doi: 10.1001/jamainternmed.2021.6850. Epub 2021 Dec 13.

IMPORTANCE: There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19.OBJECTIVE: To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen.DESIGN, SETTING, AND PARTICIPANTS:...

Cite
Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med. 2021;doi: 10.1001/jamainternmed.2021.6850.
Ortigoza, M. B., Yoon, H., Goldfeld, K. S., Troxel, A. B., Daily, J. P., Wu, Y., Li, Y., Wu, D., Cobb, G. F., Baptiste, G., O'Keeffe, M., Corpuz, M. O., Ostrosky-Zeichner, L., Amin, A., Zacharioudakis, I. M., Jayaweera, D. T., Wu, Y., Philley, J. V., Devine, M. S., Desruisseaux, M. S., Santin, A. D., Anjan, S., Mathew, R., Patel, B., Nigo, M., Upadhyay, R., Kupferman, T., Dentino, A. N., Nanchal, R., Merlo, C. A., Hager, D. N., Chandran, K., Lai, J. R., Rivera, J., Bikash, C. R., Lasso, G., Hilbert, T. P., Paroder, M., Asencio, A. A., Liu, M., Petkova, E., Bragat, A., Shaker, R., McPherson, D. D., Sacco, R. L., Keller, M. J., Grudzen, C. R., Hochman, J. S., Pirofski, L. A., Parameswaran, L., Corcoran, A. T., Rohatgi, A., Wronska, M. W., Wu, X., Srinivasan, R., Deng, F. M., Filardo, T. D., Pendse, J., Blaser, S. B., Whyte, O., Gallagher, J. M., Thomas, O. E., Ramos, D., Sturm-Reganato, C. L., Fong, C. C., Daus, I. M., Payoen, A. G., Chiofolo, J. T., Friedman, M. T., Wu, D. W., Jacobson, J. L., Schneider, J. G., Sarwar, U. N., Wang, H. E., Huebinger, R. M., Dronavalli, G., Bai, Y., Grimes, C. Z., Eldin, K. W., Umana, V. E., Martin, J. G., Heath, T. R., Bello, F. O., Ransford, D. L., Laurent-Rolle, M., Shenoi, S. V., Akide-Ndunge, O. B., Thapa, B., Peterson, J. L., Knauf, K., Patel, S. U., Cheney, L. L., Tormey, C. A., & Hendrickson, J. E. (2021). Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA internal medicine, . https://doi.org/10.1001/jamainternmed.2021.6850
Ortigoza, Mila B, et al. "Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial." JAMA internal medicine vol. (2021). doi: https://doi.org/10.1001/jamainternmed.2021.6850
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med. 2021 Dec 13; doi: 10.1001/jamainternmed.2021.6850. Epub 2021 Dec 13. PMID: 34901997.
Copy Download .nbib Format: NLM
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study.

Neurology

Antolini L, DiFrancesco JC, Zedde M, Basso G, Arighi A, Shima A, Cagnin A, Caulo M, Carare RO, Charidimou A, Cirillo M, Di Lazzaro V, Ferrarese C, Giossi A, Inzitari D, Marcon M, Marconi R, Ihara M, Nitrini R, Orlandi B, Padovani A, Pascarella R, Perini F, Perini G, Sessa M, Scarpini E, Tagliavini F, Valenti R, Vázquez-Costa JF, Villarejo-Galende A, Hagiwara Y, Ziliotto N, Piazza F.
PMID: 34531298
Neurology. 2021 Nov 02;97(18):e1809-e1822. doi: 10.1212/WNL.0000000000012778. Epub 2021 Sep 16.

BACKGROUND AND OBJECTIVES: The goal of this work was to investigate the natural history and outcomes after treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like in cerebral amyloid angiopathy-related inflammation (CAA-ri).METHODS: This was a multicenter, hospital-based, longitudinal, prospective observational study...

Cite
Antolini L, DiFrancesco JC, Zedde M, et al. Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology. 2021;97(18):e1809-e1822doi: 10.1212/WNL.0000000000012778.
Antolini, L., DiFrancesco, J. C., Zedde, M., Basso, G., Arighi, A., Shima, A., Cagnin, A., Caulo, M., Carare, R. O., Charidimou, A., Cirillo, M., Di Lazzaro, V., Ferrarese, C., Giossi, A., Inzitari, D., Marcon, M., Marconi, R., Ihara, M., Nitrini, R., Orlandi, B., Padovani, A., Pascarella, R., Perini, F., Perini, G., Sessa, M., Scarpini, E., Tagliavini, F., Valenti, R., Vázquez-Costa, J. F., Villarejo-Galende, A., Hagiwara, Y., Ziliotto, N., & Piazza, F. (2021). Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology, 97(18), e1809-e1822. https://doi.org/10.1212/WNL.0000000000012778
Antolini, Laura, et al. "Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study." Neurology vol. 97,18 (2021): e1809-e1822. doi: https://doi.org/10.1212/WNL.0000000000012778
Antolini L, DiFrancesco JC, Zedde M, Basso G, Arighi A, Shima A, Cagnin A, Caulo M, Carare RO, Charidimou A, Cirillo M, Di Lazzaro V, Ferrarese C, Giossi A, Inzitari D, Marcon M, Marconi R, Ihara M, Nitrini R, Orlandi B, Padovani A, Pascarella R, Perini F, Perini G, Sessa M, Scarpini E, Tagliavini F, Valenti R, Vázquez-Costa JF, Villarejo-Galende A, Hagiwara Y, Ziliotto N, Piazza F. Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology. 2021 Nov 02;97(18):e1809-e1822. doi: 10.1212/WNL.0000000000012778. Epub 2021 Sep 16. PMID: 34531298; PMCID: PMC8610623.
Copy Download .nbib Format: NLM
Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST).

CNS drugs

Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Fisco G, Gangitano M, Giallonardo AT, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C.
PMID: 34787838
CNS Drugs. 2021 Dec;35(12):1329-1331. doi: 10.1007/s40263-021-00868-z.

No abstract available.

Cite
Lattanzi S, Canafoglia L, Canevini MP, et al. Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST). CNS Drugs. 2021;35(12):1329-1331doi: 10.1007/s40263-021-00868-z.
Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C. (2021). Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST). CNS drugs, 35(12), 1329-1331. https://doi.org/10.1007/s40263-021-00868-z
Lattanzi, Simona, et al. "Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)." CNS drugs vol. 35,12 (2021): 1329-1331. doi: https://doi.org/10.1007/s40263-021-00868-z
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Fisco G, Gangitano M, Giallonardo AT, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C. Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST). CNS Drugs. 2021 Dec;35(12):1329-1331. doi: 10.1007/s40263-021-00868-z. PMID: 34787838; PMCID: PMC8642320.
Copy Download .nbib Format: NLM
Common variants at 21q22.3 locus influence .

iScience

Andolfo I, Russo R, Lasorsa VA, Cantalupo S, Rosato BE, Bonfiglio F, Frisso G, Abete P, Cassese GM, Servillo G, Esposito G, Gentile I, Piscopo C, Villani R, Fiorentino G, Cerino P, Buonerba C, Pierri B, Zollo M, Iolascon A, Capasso M.
PMID: 33748697
iScience. 2021 Apr 23;24(4):102322. doi: 10.1016/j.isci.2021.102322. Epub 2021 Mar 17.

The established risk factors of coronavirus disease 2019 (COVID-19) are advanced age, male sex, and comorbidities, but they do not fully explain the wide spectrum of disease manifestations. Genetic factors implicated in the host antiviral response provide for novel...

Cite
Andolfo I, Russo R, Lasorsa VA, et al. Common variants at 21q22.3 locus influence . iScience. 2021;24(4):102322doi: 10.1016/j.isci.2021.102322.
Andolfo, I., Russo, R., Lasorsa, V. A., Cantalupo, S., Rosato, B. E., Bonfiglio, F., Frisso, G., Abete, P., Cassese, G. M., Servillo, G., Esposito, G., Gentile, I., Piscopo, C., Villani, R., Fiorentino, G., Cerino, P., Buonerba, C., Pierri, B., Zollo, M., Iolascon, A., & Capasso, M. (2021). Common variants at 21q22.3 locus influence . iScience, 24(4), 102322. https://doi.org/10.1016/j.isci.2021.102322
Andolfo, Immacolata, et al. "Common variants at 21q22.3 locus influence ." iScience vol. 24,4 (2021): 102322. doi: https://doi.org/10.1016/j.isci.2021.102322
Andolfo I, Russo R, Lasorsa VA, Cantalupo S, Rosato BE, Bonfiglio F, Frisso G, Abete P, Cassese GM, Servillo G, Esposito G, Gentile I, Piscopo C, Villani R, Fiorentino G, Cerino P, Buonerba C, Pierri B, Zollo M, Iolascon A, Capasso M. Common variants at 21q22.3 locus influence . iScience. 2021 Apr 23;24(4):102322. doi: 10.1016/j.isci.2021.102322. Epub 2021 Mar 17. PMID: 33748697; PMCID: PMC7968217.
Copy Download .nbib Format: NLM
Showing 241 to 251 of 251 entries